drugset / Trial / NCT07060508
L9LS in Women of Childbearing Potential in Mali
Phase 2
Completed
279 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS) · collabHarvard School of Public Health (HSPH) · collabIndiana University · collabMalaria Research and Training Center, Bamako, Mali · collabNational Institutes of Health (NIH) · collabUniversity of Washington · collabUniversity of the Sciences, Techniques and Technologies of Bamako · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali
Timeline
- Start
- 2025-07-22
- Primary completion
- 2026-04-13
- Completion
- 2026-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L9LS | Monoclonal antibody | 1800 mg | Subcutaneous |